Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia. uri icon

Overview

abstract

  • PURPOSE: To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). DESIGN: Interventional case report. METHODS: A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. RESULTS: : The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. CONCLUSIONS: Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.

publication date

  • March 1, 2003

Research

keywords

  • Antineoplastic Agents
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Piperazines
  • Pyrimidines
  • Retinal Neoplasms

Identity

Scopus Document Identifier

  • 0344089315

Digital Object Identifier (DOI)

  • 10.1016/s0002-9394(02)01964-5

PubMed ID

  • 12614767

Additional Document Info

volume

  • 135

issue

  • 3